4-(4-hydroxybutoxy)biphenyl | 79588-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-hydroxybutoxy)biphenyl
• 英文别名: 4-(1,1'-biphenyl4-yloxy)butan-1-ol；4-[([1,1'-Biphenyl]-4-yl)oxy]butan-1-ol；4-(4-phenylphenoxy)butan-1-ol
• CAS: 79588-44-6
• 化学式: C₁₆H₁₈O₂
• mdl: MFCD12080312
• 分子量: 242.318
• InChiKey: LDHCMYHXKTWKHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-hydroxybutoxy)biphenyl 在 硫酸 、 sodium hydride 、 sodium hydrogensulfite 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 2-Hydroxy-3-[4-(4-phenylphenoxy)butoxy]propanenitrile
  参考文献：
  名称：

  α-Keto amides as inhibitors of histone deacetylase

  摘要：

  alpha-Keto ester and amides were found to be potent inhibitors of historic deacetylase. Nanomolar inhibitors against the isolated enzyme and sub-micromolar inhibitors of cellular proliferation were obtained. The alpha-keto amide 30 also exhibited significant anti-tumor effects in an in vivo tumor model. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00685-1
• 作为产物：
  描述：

  4-(4-苯基苯氧基)丁酸乙酯 在 二异丁基氢化铝 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到4-(4-hydroxybutoxy)biphenyl
  参考文献：
  名称：

  Trifluoromethyl ketones as inhibitors of histone deacetylase

  摘要：

  Trifluoromethyl ketones were found to be inhibitors of histone deacetylases (HDACs). Optimization of this series led to the identification of submicromolar inhibitors Such as 20 that demonstrated antiproliferative effects against the HT1080 and MDA 435 cell lines. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00754-0

文献信息

• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020177594A1

  公开（公告）日：2002-11-28

  Compounds having the formula 1 or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  具有以下化学式的化合物或其治疗上可接受的盐是组蛋白去乙酰化酶（HDAC）抑制剂。本文揭示了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• Ligand-free Cu-catalyzed O-arylation of aliphatic diols
  作者：Yufen Zheng、Wenxing Zou、Laichun Luo、Jiabei Chen、Songwen Lin、Qi Sun

  DOI：10.1039/c5ra12529d

  日期：——

  Coupling reaction between aryl iodides with aliphatic diols was realized with a ligand-free copper catalyst. This method was successfully applied in the process of scale-up synthesis of medicinal candidate product EMB-3.

  芳基碘化物与脂肪二醇之间的偶联反应是利用无配体铜催化剂实现的。该方法成功应用于药物候选产品EMB-3的放大合成过程中。
• Liquid Crystal Aligning Capabilities and EO characteristics of the Photoaligned TN-LCD on a Photo-crosslinkable Polyamides Based Polymer
  作者：Jeoung-Yeon Hwang、Dae-Shik Seo、Dong Suh

  DOI：10.1080/15421400490439897

  日期：2004.1

  In this work, synthesis of a photo-crosslinkable polyimide (polyimide (PI)chalcone(Chal)-biphenyl (BP)) based polymer and electro-optical (EO) performances of photoaligned twisted nematic (TN) - liquid crystal displays (LCDs) using the two kinds of the photodimerization method with obliquely polarized UV exposure on a photopolymer were investigated. High pretilt angle of the NLC was measured by polarized UV exposure using the conventional photodimerization method on the PI-Chal-BP surface for 3 min. The high pretilt angle of the NLC generated in NLC is attributable to the biphenyl moieties and the photodimerized chalcone group of the photopolymer. The NLC pretilt angle using the conventional photodimerization method was higher than that of a in-situ photodimerization method. Additionally, good voltage-transmittance (V-T) curves and response time for the photoaligned TN-LCD were observed by UV exposure on the PI-Chal-BP surface for 3 min using conventional photodimerization method. However, EO characteristics of the photoaligned TN-LCD on the PI-Chal-BP surface for 1 min using the in-situ photodimerization method were achieved.
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS
  申请人：JENKINS Helen

  公开号：US20100160351A1

  公开（公告）日：2010-06-24

  Disclosed is a pharmaceutical composition comprising (a) a first therapeutic agent, wherein the first therapeutic agent is a compound of formula II: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein; (b) a second therapeutic agent, wherein the second therapeutic agent is a uric acid synthesis inhibitor or a uricosuric agent; and (c) a pharmaceutically acceptable diluent or carrier.
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：ABBOTT LAB

  公开号：WO2002046129A2

  公开（公告）日：2002-06-13

  Compounds having the formula or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.